INFANT BACTERIAL THERAPEUTICS AB (PUBL) Inactive Instrument
Infant Bacterial Therapeutics AB (publ) Share Price Other OTC
Equities
Pharmaceuticals
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2022 | - | Sales 2023 | 0.08 6.05 | Capitalization | 1.21B 95.31B |
|---|---|---|---|---|---|
| Net income 2022 | -65M -5.11B | Net income 2023 | -123M -9.67B | EV / Sales 2022 | - |
| Net cash position 2022 | 336M 26.4B | Net cash position 2023 | 329M 25.87B | EV / Sales 2023 | 11,472,257,143 x |
| P/E ratio 2022 |
-8.58
x | P/E ratio 2023 |
-9.04
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 87.87% |
More Fundamentals
* Assessed data
More news
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 57 | 31/12/12 | |
Maria Ekdahl
DFI | Director of Finance/CFO | 51 | 18/09/22 |
| Chief Operating Officer | 57 | 19/10/14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Margareta Hagman
BRD | Director/Board Member | 58 | 23/09/15 |
| Chairman | 74 | 31/12/10 | |
Anthon Jahreskog
BRD | Director/Board Member | 44 | 03/05/17 |
Infant Bacterial Therapeutics AB is a Sweden-based company, which is primarily involved in the pharmaceutical industry. The Company develops drugs that meet the needs of the premature infant. The Companyâs focus is on clinical development of IBP-9414, a drug candidate containing Lactobacillus reuteri, in the prevention of necrotizing enterocolitis (NEC), a fatal disease that affects premature infants.
Sector
Pharmaceuticals
Calendar
28/08/2024
- Q2 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| +18.88% | 80.5B | |
| +14.11% | 9.15B | |
| -14.14% | 4.9B | |
| +43.39% | 4.49B | |
| +18.90% | 4.44B | |
| +7.93% | 2.19B | |
| -28.40% | 2.13B | |
| +15.93% | 2.1B | |
| -43.17% | 1.78B |
